Researchers find recurrent type of brain cancer tumor not a clone of the original

January 14, 2016 by Bob Yirka report
Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute

(Medical Xpress)—An international team of researchers has found evidence that shows that cancers that reoccur in patients with medulloblastomas are not necessarily derived from the same source as the original tumor. In their paper published in the journal Nature, the team describes genetic work they did with mouse models and then with whole-genome sequencing on human tumors, what they found and what they believe needs to happen to better treat patients going forward.

Medulloblastomas are a deadly form of cancerous that forms in the part of the brain near the base of the skull—they are notably different from other because they tend to spread to other parts of the brain and/or spinal column. They are also particularly aggressive and have a high rate of return when removed surgically and sadly, are diagnosed most often in children. In this new effort, the researchers sought to learn whether tumors that form after first onset tumors have been removed surgically, are genetically the same as the original tumor. This is important because treatments given after surgery are custom designed to fight off new tumor growth based on the genetic profile of the original tumor.

To find out, the researchers used the Sleeping Beauty transposon system to cause the development of Medulloblastomas in test mice. They then followed that up by mimicking the typical treatment progression prescribed for humans—approximately 60 percent of them relapsed. Tissue samples were retrieved from both the original and relapse tumors and sequencing was performed. The team reports that they were able to identify 23 common insertion sites in 11 original tumors and 40 in the recurrent tumors and that the insertion sites were "extremely different" between the two. The team then conducted whole genome sequencing on a small sample of human tumors, both original and recurrent. They report "striking" genetic differences between the original and recurrent tumors.

The researchers conclude by suggesting that recurrent medulloblastomas are not the result of re-growth of the original tumor but are instead likely the result of from an unrelated sub-tumor that had not been targeted by treatments. They suggest that future clinical trials include additional biopsies to identify sub-tumors for targeting by separate treatments.

Explore further: New sequencing technique reveals genetic clues to rare breast tumors

More information: A. Sorana Morrissy et al. Divergent clonal selection dominates medulloblastoma at recurrence, Nature (2016). DOI: 10.1038/nature16478

Abstract
The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon–driven, functional genomic mouse model of medulloblastoma with 'humanized' in vivo therapy (microneurosurgical tumour resection followed by multi-fractionated, image-guided radiotherapy). Genetic events in recurrent murine medulloblastoma exhibit a very poor overlap with those in matched murine diagnostic samples (<5%). Whole-genome sequencing of 33 pairs of human diagnostic and post-therapy medulloblastomas demonstrated substantial genetic divergence of the dominant clone after therapy (<12% diagnostic events were retained at recurrence). In both mice and humans, the dominant clone at recurrence arose through clonal selection of a pre-existing minor clone present at diagnosis. Targeted therapy is unlikely to be effective in the absence of the target, therefore our results offer a simple, proximal, and remediable explanation for the failure of prior clinical trials of targeted therapy.

Related Stories

Predicting cancer's growth from few clues

November 2, 2015

Mathematicians at Duke University are developing ways to help doctors predict how different cancers are likely to progress when actual measurements of tumor growth are hard to come by.

Genetic mutations differ within a single tumor, study finds

December 2, 2015

When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations. The findings could have significant implications for treatment ...

Cancer-killing proteins destroy tumor cells in bloodstream

January 12, 2016

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. ...

Recommended for you

Oxygen can impair cancer immunotherapy in mice

August 25, 2016

Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers. This mechanism involves oxygen inhibition of the anticancer ...

Stem cell propagation fuels cancer risk in different organs

August 25, 2016

The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community. Some researchers maintain that environmental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.